Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Imatinib Mesylate 28nilotinib 21Cytarabine 21Methotrexate 16Hydroxyurea 15Cyclophosphamide 15Busulfan 15Peripheral Blood Stem Cell Transplantation 13ruxolitinib 11Etoposide 11Whole-Body Irradiation 10fludarabine phosphate 9fludarabine 9Tacrolimus 9Mycophenolic Acid 9Daunorubicin 9Idarubicin 8Radiotherapy 7Mitoxantrone 7Interferon-alpha 7Cyclosporine 6peginterferon alfa-2a 5bosutinib 5asciminib 5Melphalan 5Azacitidine 5merphos 4luspatercept 4Thioguanine 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × guadecitabine × Myeloid × Clear all
NCT02907359 2024-08-27

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Astex Pharmaceuticals, Inc.

Phase 3 Completed
417 enrolled 24 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡